BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 10522573)

  • 1. Ganciclovir resistance in a heart transplant recipient infected by cytomegalovirus.
    Manso JV; Lambert JL; Oña M; de la Iglesia JL; Iglesias J
    Int J Cardiol; 1999 Sep; 71(1):97-8. PubMed ID: 10522573
    [No Abstract]   [Full Text] [Related]  

  • 2. Letermovir successfully used for secondary prophylaxis in a heart transplant recipient with ganciclovir-resistant cytomegalovirus syndrome (UL97 mutation).
    Chong PP; Teiber D; Prokesch BC; Arasaratnam RJ; Peltz M; Drazner MH; Garg S
    Transpl Infect Dis; 2018 Oct; 20(5):e12965. PubMed ID: 29989279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Foscarnet therapy of ganciclovir-resistant cytomegalovirus in marrow transplantation.
    Drobyski WR; Knox KK; Carrigan DR; Ash RC
    Transplantation; 1991 Jul; 52(1):155-7. PubMed ID: 1650043
    [No Abstract]   [Full Text] [Related]  

  • 4. Combination antiviral therapy for ganciclovir-resistant cytomegalovirus infection in solid-organ transplant recipients.
    Mylonakis E; Kallas WM; Fishman JA
    Clin Infect Dis; 2002 May; 34(10):1337-41. PubMed ID: 11981729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants.
    Limaye AP; Corey L; Koelle DM; Davis CL; Boeckh M
    Lancet; 2000 Aug; 356(9230):645-9. PubMed ID: 10968438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ganciclovir-resistant cytomegalovirus encephalitis in a bone marrow transplant recipient.
    Julin JE; van Burik JH; Krivit W; Webb C; Holman CJ; Clark HB; Balfour HH
    Transpl Infect Dis; 2002 Dec; 4(4):201-6. PubMed ID: 12535263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Case study: rapid emergence of a cytomegalovirus UL97 mutant in a heart-transplant recipient on pre-emptive ganciclovir therapy.
    Gilbert C; LeBlanc MH; Boivin G
    Herpes; 2001 Nov; 8(3):80-2. PubMed ID: 11867025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ganciclovir resistance: a matter of time and titre.
    Drew WL
    Lancet; 2000 Aug; 356(9230):609-10. PubMed ID: 10968428
    [No Abstract]   [Full Text] [Related]  

  • 9. UL54 foscarnet mutation in an hematopoietic stem cell transplant recipient with cytomegalovirus disease.
    Gregg K; Hakki M; Kaul DR
    Transpl Infect Dis; 2014 Apr; 16(2):320-3. PubMed ID: 24621186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Four dually resistant human cytomegalovirus strains from AIDS patients: single mutations in UL97 and UL54 open reading frames are responsible for ganciclovir- and foscarnet-specific resistance, respectively.
    Baldanti F; Sarasini A; Silini E; Barbi M; Lazzarin A; Biron KK; Gerna G
    Scand J Infect Dis Suppl; 1995; 99():103-4. PubMed ID: 8668930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of ganciclovir resistance during treatment of primary cytomegalovirus infection after liver transplantation.
    Rosen HR; Benner KG; Flora KD; Rabkin JM; Orloff SL; Olyaei A; Chou S
    Transplantation; 1997 Feb; 63(3):476-8. PubMed ID: 9039944
    [No Abstract]   [Full Text] [Related]  

  • 12. Drug resistance in cytomegalovirus: current knowledge and implications for patient management.
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996; 12 Suppl 1():S1-22. PubMed ID: 8680897
    [No Abstract]   [Full Text] [Related]  

  • 13. CMV resistance: "more complicated than we thought".
    Mascolini M
    J Int Assoc Physicians AIDS Care; 1996 May; 2(5):37-9. PubMed ID: 11363529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of multidrug-resistant CMV infection in immunocompromised patients: case report of a heart-transplant recipient and review of the literature.
    Deback C; Burrel S; Varnous S; Carcelain G; Conan F; Aït-Arkoub Z; Autran B; Gandjbakhch I; Agut H; Boutolleau D
    Antivir Ther; 2015; 20(2):249-54. PubMed ID: 25219330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Viral monitoring and successful treatment of a ganciclovir-resistant cytomegalovirus infection in a heart transplant recipient.
    García-Martínez J; Folgueira L; Delgado R; Hernando S; Prieto C; Aguado JM; Otero JR
    Transpl Infect Dis; 2008 Apr; 10(2):123-8. PubMed ID: 17605746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Case report: Multidrug-resistant cytomegalovirus in a modified multivisceral transplant recipient.
    Goldsmith PM; Husain MM; Carmichael A; Zhang H; Middleton SJ
    Transplantation; 2012 Apr; 93(7):e30-2. PubMed ID: 22450598
    [No Abstract]   [Full Text] [Related]  

  • 17. Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease.
    Chou S; Marousek G; Guentzel S; Follansbee SE; Poscher ME; Lalezari JP; Miner RC; Drew WL
    J Infect Dis; 1997 Sep; 176(3):786-9. PubMed ID: 9291334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients.
    Erice A; Gil-Roda C; Pérez JL; Balfour HH; Sannerud KJ; Hanson MN; Boivin G; Chou S
    J Infect Dis; 1997 May; 175(5):1087-92. PubMed ID: 9129070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistance to combined ganciclovir and foscarnet therapy in a liver transplant recipient with possible dual-strain cytomegalovirus coinfection.
    Rodriguez J; Casper K; Smallwood G; Stieber A; Fasola C; Lehneman J; Heffron T
    Liver Transpl; 2007 Oct; 13(10):1396-400. PubMed ID: 17902124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful treatment with foscarnet for ganciclovir-resistant cytomegalovirus infection in a kidney transplant recipient: A case report.
    Iwami D; Ogawa Y; Fujita H; Morita K; Sasaki H; Oishi Y; Higuchi H; Hatanaka K; Shinohara N
    Nephrology (Carlton); 2016 Jul; 21 Suppl 1():63-6. PubMed ID: 26970406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.